Topics

Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis

09:21 EDT 30 Apr 2019 | Labiotech.eu

Founded in March this year, Alentis Therapeutics has bagged a Series A round of €11.1M (CHF 12.5M) to develop antibody drugs treating liver fibrosis, which currently has no approved treatments. Liver fibrosis is the scarring of liver tissue, which can happen as a consequence of aging, chronic hepatitis or conditions such as non-alcoholic steatohepatitis (NASH). […]

The post Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis appeared first on Labiotech.eu.

Original Article: Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis

NEXT ARTICLE

More From BioPortfolio on "Swiss Biotech Raises €11M to Develop Treatments for Liver Fibrosis"

Quick Search

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...